Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of July 2023, specifically dated July 17, 2023. The report details a registered direct offering of ordinary shares to raise capital through a definitive securities purchase agreement with institutional investors.
Key Financial Metrics
- Offering Size: 8,500,000 ordinary shares.
- Price Per Share: $1.00.
- Gross Proceeds: $8,500,000.
- Placement Fee: 7.0% of gross proceeds (paid to A.G.P./Alliance Global Partners).
- Net Proceeds: Not explicitly stated in the filing text; calculated gross proceeds are $8,500,000 less the 7.0% fee.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational financial metrics as this is a transactional filing rather than a periodic financial report.
Material Changes
The primary material change is the agreement to issue and sell 8,500,000 new ordinary shares, which will increase the company's share count and dilute existing shareholders. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
- Closing Date: Expected on or about July 19, 2023, subject to customary closing conditions.
- Lock-Up Provisions: Evogene agreed not to issue or announce the issuance of ordinary shares or equivalents for 75 days from the agreement date. Additionally, the company agreed not to enter into variable rate transactions for six months.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to risks beyond the company's control, including conditions for the closing of the offering.
- Unusual Items: None identified beyond the standard capital raise transaction.
Investor Verification Checklist
- Verify the final closing date of the offering (expected July 19, 2023).
- Confirm the exact net proceeds after deducting the 7.0% placement fee and other transaction costs.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific customary exceptions to the lock-up provisions.
- Check the updated share count and dilution impact on existing shareholders post-closing.
- Review the press release (Exhibit 99.1) for additional details on the use of proceeds.